文献速递甲状腺核医学核素与放射性配体治疗

177Lu-DOTATATE治疗放射性碘难治性分化型甲状腺癌:单中心经验

177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience.
PubMed 文献 · Clin Nucl Med · 2018-01-01

结果显示仅1例患者达部分缓解,3例为疾病进展,1例影像学稳定但Tg升高,提示疗效异质。

要点

  • 5例RrDTC患者接受177Lu-DOTATATE治疗2至4个周期,仅1例达部分缓解。
  • 3例患者出现疾病进展,1例影像学稳定但Tg升高。
  • 尽管治疗前PET显示病灶摄取良好,177Lu-DOTATATE疗效仍呈异质性。

核心结论

  • 在这项5例患者的病例研究中,尽管治疗前PET显示病灶摄取良好,177Lu-DOTATATE治疗在RrDTC患者中仅显示异质性的疗效。

主要发现

  • 治疗后评估中,5例患者仅1例达部分缓解。
  • 3例患者为疾病进展。
  • 1例患者影像学结果稳定但Tg水平升高,两者不一致。

局限性

  • 原文为病例研究,样本量为5例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by Ga/Lu-DOTATATE could evolve as a novel theranostic option. METHODS: Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using Ga-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with Lu-DOTATATE. Response to therapy was assessed by thyroglobulin (Tg) and morphological and metabolic criteria based on interim and follow-up Ga-DOTATATE-PET/CTs. Analysis was performed on a per-patient basis. RESULTS: In the post-therapy evaluation, only one out of five patients showed a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels. CONCLUSION: In this case study of five patients, Lu-DOTATATE therapy showed only heterogeneous response and efficacy in RrDTC patients despite good lesional uptake in pre-therapeutic PET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Roll W, Riemann B, Schäfers M, et al. 177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience. Clin Nucl Med. 2018. PMID: 30059430. doi:10.1097/RLU.0000000000002219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。